The U.S. Senate on Tuesday voted 69-30 to pass a bipartisan infrastructure bill that includes two drug pricing provisions, neither directly 340B-related. The bill now moves to the U.S. House, which is on a seven-week summer break. The $1 trillion bill includes $550 billion in new spending.
One of the infrastructure bill’s drug pricing provisions would require drug manufacturers to refund Medicare for the discarded portion of Part B drugs that are packaged for single use. The other would push back, to Jan. 1, 2026, the effective date of the Trump administration’s final regulation aimed at eliminating the rebates drug companies pay to PBMs in Medicare Part D and Medicaid managed care for more favorable placement on drug formularies.
The U.S. Senate on Tuesday voted 69-30 to pass a bipartisan infrastructure bill that includes two drug pricing provisions, neither directly 340B-related. The bill now moves to the U.S. House, which is on a seven-week summer break. The $1 trillion bill includes $550 billion in new spending.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.